{"id":"elvitegravir-cobicistat-emtricitabine-tenofovir","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Elevated creatinine"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Elvitegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV DNA from integrating into the host genome. Cobicistat is a pharmacokinetic booster that inhibits CYP3A4, increasing elvitegravir levels. Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) that block reverse transcriptase and prevent viral RNA conversion to DNA. Together, these agents target multiple steps of the HIV replication cycle.","oneSentence":"This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication by inhibiting integrase, blocking protease activity, and inhibiting reverse transcriptase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:19.739Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 infection in adolescents and children (weight-based dosing)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT01854775","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05-06","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":129},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT02859558","phase":"PHASE2","title":"Early ART to Limit Infection and Establishment of Reservoir","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2017-01-24","conditions":"HIV-1 Infection","enrollment":195},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT03205696","phase":"","title":"Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2017-08-01","conditions":"Human Immunodeficiency Virus","enrollment":101},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT05064020","phase":"","title":"Bictegravir in the Elderly Living With HIV (BICEP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2020-08-01","conditions":"HIV-1-infection","enrollment":162},{"nctId":"NCT03493568","phase":"PHASE3","title":"Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)","status":"TERMINATED","sponsor":"IRCCS San Raffaele","startDate":"2017-02-06","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT03717129","phase":"PHASE4","title":"Analysis of Crushed and Whole Tablet Genvoya","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2019-04-15","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT04040075","phase":"PHASE4","title":"Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy","status":"TERMINATED","sponsor":"Southampton Healthcare, Inc.","startDate":"2019-07-01","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT02660905","phase":"PHASE3","title":"HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-04","conditions":"Human Immunodeficiency Virus, Hepatitis C, Chronic","enrollment":25},{"nctId":"NCT01815580","phase":"PHASE4","title":"HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-07","conditions":"HIV","enrollment":225},{"nctId":"NCT03251144","phase":"PHASE1, PHASE2","title":"Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2019-04-01","conditions":"HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction","enrollment":26},{"nctId":"NCT01855867","phase":"PHASE4","title":"HIV Non-Occupational Post-Exposure Prophylaxis","status":"COMPLETED","sponsor":"Kenneth H. Mayer, MD","startDate":"2013-05","conditions":"Human Immunodeficiency Virus","enrollment":100},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03447873","phase":"PHASE4","title":"Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2017-06-01","conditions":"HIV Infections","enrollment":153},{"nctId":"NCT03976752","phase":"PHASE1","title":"Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-03-13","conditions":"HIV/AIDS","enrollment":41},{"nctId":"NCT01815736","phase":"PHASE3","title":"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":1443},{"nctId":"NCT02325934","phase":"PHASE1","title":"Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-02","conditions":"HIV","enrollment":24},{"nctId":"NCT03405935","phase":"PHASE3","title":"Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-03-01","conditions":"HIV-1 Infection","enrollment":86},{"nctId":"NCT02600819","phase":"PHASE3","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-14","conditions":"HIV-1 Infection","enrollment":55},{"nctId":"NCT03472963","phase":"PHASE1","title":"Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-04-27","conditions":"HIV Infections","enrollment":35},{"nctId":"NCT03693508","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2018-04-13","conditions":"HIV Infections, Severe Immunosuppression","enrollment":50},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT03405194","phase":"NA","title":"Same-Day Treatment With Genvoya vs. EFV/TDF/3TC","status":"WITHDRAWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2018-05-01","conditions":"HIV/AIDS","enrollment":""},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02652624","phase":"PHASE3","title":"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-02-19","conditions":"HIV-1 Infection","enrollment":472},{"nctId":"NCT01818596","phase":"PHASE3","title":"Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":252},{"nctId":"NCT01797445","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-12","conditions":"HIV, HIV Infections","enrollment":872},{"nctId":"NCT03067285","phase":"PHASE4","title":"A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-09-08","conditions":"HIV Infections","enrollment":39},{"nctId":"NCT03549312","phase":"PHASE4","title":"Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy","status":"UNKNOWN","sponsor":"Saskatchewan Health Authority - Regina Area","startDate":"2018-02-01","conditions":"HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence","enrollment":25},{"nctId":"NCT02251236","phase":"NA","title":"Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-01","conditions":"HIV","enrollment":14},{"nctId":"NCT01705574","phase":"PHASE3","title":"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10-24","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":583},{"nctId":"NCT02985996","phase":"PHASE1","title":"Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities","status":"COMPLETED","sponsor":"Emory University","startDate":"2017-02-06","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT03425994","phase":"","title":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2018-02-06","conditions":"Chronic Hepatitis B in HIV Patient, Kidney Injury, Bone Diseases","enrollment":275},{"nctId":"NCT03877536","phase":"NA","title":"Antiretroviral Therapy for Acute HIV Infection","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2019-03-17","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT02998320","phase":"PHASE3","title":"Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis","status":"COMPLETED","sponsor":"Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux","startDate":"2017-03-10","conditions":"HIV Risk","enrollment":101},{"nctId":"NCT01497899","phase":"PHASE2","title":"Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-12-28","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":279},{"nctId":"NCT02276612","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-03","conditions":"HIV","enrollment":60},{"nctId":"NCT01780506","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-12-26","conditions":"HIV, HIV Infections","enrollment":872},{"nctId":"NCT02071082","phase":"PHASE3","title":"Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-02-25","conditions":"HIV, HBV","enrollment":79},{"nctId":"NCT01968551","phase":"PHASE3","title":"Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-03","conditions":"HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":158},{"nctId":"NCT01967940","phase":"PHASE3","title":"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10-25","conditions":"HIV, HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":55},{"nctId":"NCT02707601","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-01","conditions":"HIV-1 Infection, HCV Infection","enrollment":150},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01721109","phase":"PHASE2, PHASE3","title":"Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-12-06","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":50},{"nctId":"NCT02180438","phase":"PHASE4","title":"An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal","status":"COMPLETED","sponsor":"University of Washington","startDate":"2014-09","conditions":"HIV-2 Infection","enrollment":30},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT02199613","phase":"PHASE4","title":"Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2014-10","conditions":"HIV Infection","enrollment":10},{"nctId":"NCT02475135","phase":"PHASE1","title":"Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-06-01","conditions":"Healthy","enrollment":72},{"nctId":"NCT03092206","phase":"PHASE1","title":"Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2017-04-18","conditions":"Insulin Resistance","enrollment":30},{"nctId":"NCT02477527","phase":"PHASE4","title":"Atripla to Stribild Switch Study to Evaluate Sleep Disturbances","status":"COMPLETED","sponsor":"Midtown Medical Center, Tampa, FL","startDate":"2015-02","conditions":"HIV, AIDS, Sleep Disorders","enrollment":21},{"nctId":"NCT01929759","phase":"NA","title":"Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":"HIV Disease","enrollment":10},{"nctId":"NCT02351908","phase":"PHASE4","title":"Renal Integrase Study","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-03","conditions":"HIV","enrollment":60},{"nctId":"NCT01694420","phase":"PHASE3","title":"Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet","status":"COMPLETED","sponsor":"Duke University","startDate":"2012-09","conditions":"HIV","enrollment":33},{"nctId":"NCT02198443","phase":"PHASE4","title":"Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2015-06-06","conditions":"HIV","enrollment":160},{"nctId":"NCT02219217","phase":"PHASE1","title":"SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2014-10","conditions":"HIV","enrollment":17},{"nctId":"NCT02220868","phase":"PHASE4","title":"Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study","status":"COMPLETED","sponsor":"Saint Michael's Medical Center","startDate":"2014-07","conditions":"Hepatitis C Infection, HIV Infection","enrollment":10},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT01363011","phase":"PHASE3","title":"Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-05","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":106},{"nctId":"NCT02283060","phase":"PHASE4","title":"Sleep and Cognition After Atripla to Stribild Switch","status":"UNKNOWN","sponsor":"University of Hawaii","startDate":"2014-09","conditions":"HIV","enrollment":30},{"nctId":"NCT01495702","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-12","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":439},{"nctId":"NCT01106586","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-04","conditions":"HIV, HIV Infections","enrollment":708},{"nctId":"NCT01095796","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03","conditions":"HIV, HIV Infections","enrollment":707},{"nctId":"NCT02306577","phase":"","title":"STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)","status":"UNKNOWN","sponsor":"Vancouver Infectious Diseases Centre","startDate":"2014-11","conditions":"HIV, Illicit Drug User","enrollment":30},{"nctId":"NCT01533259","phase":"PHASE3","title":"Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-01","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":48},{"nctId":"NCT02203461","phase":"PHASE1","title":"Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2014-07","conditions":"Insulin Resistance","enrollment":30},{"nctId":"NCT00869557","phase":"PHASE2","title":"Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-04","conditions":"HIV, HIV Infections","enrollment":71},{"nctId":"NCT01005290","phase":"PHASE2","title":"A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure","status":"TERMINATED","sponsor":"Ferrer Internacional S.A.","startDate":"2009-10","conditions":"Hypertension","enrollment":38}],"_emaApprovals":[],"_faersSignals":[{"count":46,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"},{"count":28,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"},{"count":23,"reaction":"ABORTION SPONTANEOUS"},{"count":23,"reaction":"PRODUCT USE ISSUE"},{"count":21,"reaction":"OFF LABEL USE"},{"count":20,"reaction":"PNEUMONIA"},{"count":19,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":14,"reaction":"DEATH"},{"count":14,"reaction":"NEOPLASM MALIGNANT"},{"count":11,"reaction":"WEIGHT INCREASED"}],"_approvalHistory":[],"publicationCount":127,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Stribild"],"phase":"marketed","status":"active","brandName":"elvitegravir/cobicistat/emtricitabine/tenofovir","genericName":"elvitegravir/cobicistat/emtricitabine/tenofovir","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication by inhibiting integrase, blocking protease activity, and inhibiting reverse transcriptase. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}